Laidlaw cut shares of Clearside Biomedical (NASDAQ:CLSD) from a buy rating to a hold rating in a report issued on Tuesday morning, The Fly reports.

Other equities analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Clearside Biomedical from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Clearside Biomedical from a hold rating to a strong-buy rating and set a $1.50 target price for the company in a research note on Monday. Needham & Company LLC downgraded shares of Clearside Biomedical from a buy rating to a hold rating in a research note on Friday, August 9th. JMP Securities lowered their target price on shares of Clearside Biomedical from $12.00 to $4.00 and set an outperform rating for the company in a research note on Monday. Finally, Wedbush reissued a buy rating and issued a $4.00 price target on shares of Clearside Biomedical in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $3.79.

NASDAQ:CLSD opened at $1.16 on Tuesday. The company has a fifty day simple moving average of $1.13 and a two-hundred day simple moving average of $1.24. The company has a market cap of $48.33 million, a price-to-earnings ratio of -0.43 and a beta of -0.88. The company has a quick ratio of 3.04, a current ratio of 3.47 and a debt-to-equity ratio of 0.69. Clearside Biomedical has a 52 week low of $0.95 and a 52 week high of $7.13.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts expect that Clearside Biomedical will post -0.98 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in Clearside Biomedical by 63.4% during the 1st quarter. SG Americas Securities LLC now owns 57,234 shares of the company’s stock worth $79,000 after buying an additional 22,213 shares during the period. Parallel Advisors LLC purchased a new stake in Clearside Biomedical during the 1st quarter worth $87,000. Virtu Financial LLC increased its stake in Clearside Biomedical by 29.5% during the 1st quarter. Virtu Financial LLC now owns 69,027 shares of the company’s stock worth $95,000 after buying an additional 15,712 shares during the period. A.R.T. Advisors LLC purchased a new stake in Clearside Biomedical during the 2nd quarter worth $95,000. Finally, Jane Street Group LLC purchased a new stake in Clearside Biomedical during the 2nd quarter worth $98,000. 15.89% of the stock is currently owned by hedge funds and other institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Recommended Story: Compound Interest and Why It Matters When Investing

The Fly

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.